{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:07Z","timestamp":1793933707031,"version":"4.8.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,16]]},"DOI":"10.1182\/blood.2025030526","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:32:05Z","timestamp":1760628725000},"page":"1874-1875","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["BCMA: BeCoMing a new hope for AL amyloidosis"],"prefix":"10.1182","volume":"146","author":[{"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2025101611320090700_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2025028383","article-title":"Safety and efficacy of elranatamab in patients with relapsed and\/or refractory immunoglobulin light-chain amyloidosis","volume":"146","author":"Vianna","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2025101611320090700_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025101611320090700_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA Working Group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"2025101611320090700_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","article-title":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025101611320090700_bib5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025101611320090700_bib6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2024-203254","article-title":"Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: an updated analysis of a phase 2 study by the European myeloma network [abstract]","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2025101611320090700_bib7","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","volume":"43","author":"Lebel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025101611320090700_bib8","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"13","key":"2025101611320090700_bib9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/16\/1874\/2416927\/blood_bld-2025-030526-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/16\/1874\/2416927\/blood_bld-2025-030526-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:32:07Z","timestamp":1760628727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/16\/1874\/547615\/BCMA-BeCoMing-a-new-hope-for-AL-amyloidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":9,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,10,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030526","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,16]]},"published":{"date-parts":[[2025,10,16]]}}}